上海，2025年1月14日 - 泰励生物，一家致力于开发针对耐药肿瘤创新疗法的临床阶段的生物技术公司，宣布公司CEO兼联合创始人张彦涛博士受邀于2025年1月16日星期四下午1:15（太平洋时间；北京时间1月17日星期五上午5:15），在第43届摩根大通全球医疗健康年会上报告公司研发进展。

请访问泰励生物官网“Corporate News”
https://en.tyligand.com.cn/tyligand-news/news-release 观看演讲的现场网络直播。此外，会议结束后至少14天内将提供回放。

关于泰励生物

泰励生物（Tyligand Bioscience）成立于2018年，是一家临床阶段生物技术公司，专注于癌症创新疗法的发现和开发。除了正积极推向全球多中心临床试验的高选择性 KRAS G12D 抑制剂 TSN1611 项目外，公司临床管线还包括 II 型多靶点激酶抑制剂 TSN084、首个双功能肿瘤免疫激动剂 (DATIA) TSN222，以及具有独特连接子和新颖有效负载的抗体药物偶联物 (ADC) 研发平台。

有关Tyligand Bioscience的更多信息，请访问 www.tyligand.com

Tyligand Bioscience invited to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Shanghai, January 14th, 2025 - Tyligand Bioscience, a clinical-stage biotechnology company dedicated to developing innovative therapeutics against drug resistant tumors, today announced that Tony Zhang, Ph.D., the company’s Chief Executive Officer and Co-founder, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 1:15 p.m. PST in San Francisco. 

To access the live webcast of the presentation, please visit the “Corporate News” page of Tyligand Bioscience’s website at
https://en.tyligand.com.cn/tyligand-news/news-release.
Additionally, a replay will be available for at least 14 days following the conference.

About Tyligand Bioscience

Founded in 2018, Tyligand Bioscience is a clinical stage biotech focusing on the discovery and development of transformative therapies for cancer. In addition to the highly selective and orally bioavailable KRAS G12D inhibitor TSN1611, which is actively being advanced into global multicenter clinical trials, the company has several molecules in development, including TSN084, a Type II multi-kinase inhibitor; TSN222, a first in kind dual acting tumor immune agonist (DATIA), and a platform for antibody drug conjugates (ADCs) featuring proprietary linkers and novel payloads.

For more information about Tyligand Bioscience, please visit www.tyligand.com